
GSK Plc plans to invest GBP 1bn (USD 1.2bn) over a decade to accelerate work on new medicines and vaccines to combat malaria, tuberculosis, HIV, neglected tropical diseases and antibiotic resistance.
The UK drugmaker said it has also formed a global health unit focused on the prevention and treatment of infectious diseases that disproportionately affect lower-income nations, an area that’s not usually profitable. The unit will have a “ring-fenced” budget, with results measured by health impact rather than financial returns, said Thomas Breuer, the company’s chief global health officer.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app